Skip to main content
Summit Health provides state-of-the-art medical advances and technology by offering novel treatment options to patients through clinical research.

Our Research Review Committee is comprised of Summit Health physicians and staff who manage all medical clinical trials, determine the scientific/ethical merits, and identify the potential impact of clinical research on patients.

What is Clinical Research?

Also known as clinical trials, clinical research involves patients who might benefit from new treatments that are not yet available. Research physicians use clinical research to test a medication, device, treatment approach, or medication dose. All research includes a panel of experts, also known as physician investigators, who decide how best to use the new treatment. The investigators also identify the types of patients who are likely to benefit most from the treatment. To be eligible for a clinical trial, the patients must fit certain criteria.

During a clinical trial, the researchers track and make note of all the changes (data) subjects experience as a result of the treatment they are given. The data are then used to make decisions about whether to use the medication, device, or treatment for a wide range of patients.

People who participate in medical research and clinical trials are volunteers. 

In general, clinical research helps determine whether:

  • A new medication, device, treatment, or dose is safe and effective for a specific type of patient
  • An already marketed medication or device can be used for a different disease or condition than the one for which it was originally intended
  • A new medication, device, or treatment is more effective than previous treatments for a disease or condition

Medical clinical trials also sometimes compare more than one medication, device, or treatment to determine which is the most effective.

What to Expect

Better research helps researchers and practitioners understand a disease, condition, or disability as well as examine and develop ways to prevent, diagnose, treat and improve quality of life.

It is the foundation of advances in healthcare processes, treatments, and technologies.

Clinical research helps determine whether treatments are safe and effective. It is used to help improve quality of life for people who are experiencing temporary as well as ongoing (chronic) illness. Clinical research can give participants hope for overcoming a disease or condition.

Types of Clinical Research Include:

  • Natural history studies to gather information about health and disease
  • Screening trials to identify how to detect a disease or condition
  • Diagnostic trials to determine best tests or procedures for diagnoses
  • Treatment trials that include medication(s), surgery, procedures, and other therapies
  • Prevention trials, including medication, vaccines, and lifestyle changes to help prevent disease from occurring and recurring
  • Quality of life (or supportive care) trials to identify ways to improve quality of life for people with chronic illness

About Clinical Research

All clinical research in the United States is conducted with the review and approval of an accredited, independent review board (IRB) comprised of physicians, and statisticians. The IRB reviews each clinical trial before and during research to ensure the trial is ethical, participants’ rights are protected, and that risks are minimal.

Clinical research involves a plan known as a protocol that:

  • Identifies the purpose of the trial
  • Outlines who can participate (eligibility)
  • Defines how long the study will last (study duration) and its phases
  • Describes the treatments, including frequency and dosages of medication
  • Gives details about tests and procedures
  • Identifies the researchers, including a principal investigator and coinvestigator(s)
  • Specifies information the researchers will gather
  • Suggests whether the data will be published

Informed consent is an important part of the clinical research process. It helps people decide whether to participate in a clinical trial. During informed consent, researchers explain details of the study, including its purpose, length, treatments involved, required tests and procedures, and benefits and risks. Participants also are given contact information so that participants know whom to call to get answers to their questions. Once a trial is underway, participants continue receiving information about the trial as part of informed consent.

All participants must sign a document of informed consent to engage in clinical research.

Informed consent is not a contract. All participants for clinical research are considered volunteers who are free deny treatments, test, or procedures as well as withdraw from the study. In some cases, however, denying treatments, tests, or procedures can mean being unable to complete (or becoming ineligible for) the trial.

Summit Providers

Our Research Team

Clinical researchers learn about disease processes when they compare healthy volunteers with patient groups in a clinical trial.

View Our Specialists

Enrolling in Clinical Research

Before enrolling in clinical research, potential participants must qualify for it.

If you are considering enrolling in clinical research, you should consider:

  • Risks, including:
    • Unpleasant side effects it might cause
    • Potential complications that require additional medical attention
    • Visits to the study site and time it takes from your other activities
    • The need for additional treatments, test, and hospital stays
    • Possible costs to you for traveling to the study site
  • Benefits, including:
    • Having an active role in your health care
    • Access to new treatments before they are available to others
    • Receiving medical care and attention from doctors and other health care practitioners
    • Contributing to the health and well-being of others

Once a new treatment, device, or intervention is proven safe and effective in clinical research, it can become a standard of medical practice.

For All Oncology Trials

Contact Michelle Mackenzie, RN, OCN, CRC at 973-436-1755 or mmackenzie@summithealth.com.

For All Other Studies

Contact Kelly Ritter, LPN, CCRC at 908-721-5673 or kritter@summithealth.com.


Current Active Trials - Last Updated May 10, 2022

In addition to the below trials, Summit Health has access to the Tempus TIME Trial™ Program which seeks to rapidly match patients to targeted clinical trials.

Service Type Principal Investigator Title Description
Cancer Services Breast Dr. Steven Papish

PART D OPEN- 2 weeks on 1 week off q 3 weeks
1st line Metastatic Triple Negative BC NCT03310957

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic 
Triple Negative Breast Cancer
Cancer Services Breast Dr. Steven Papish COMING SOON 
1st Line Met. TNBC - PD-L1+
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and
Pembrolizumab Versus Treatment of Physician’s Choice and
Pembrolizumab in Patients With Previously Untreated, Locally Advanced,
Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors
Express PD-L1
Cancer Services Breast Dr. Steven Papish COMING SOON
1st Line Met. TNBC - PD-L1
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
Cancer Services Breast Dr. Steven Papish COMING SOON
1st Line Met TNBC
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for
PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02)
Cancer Services Breast Dr. Winnie Polen

COMING SOON
Invasive Breast Cancer or DCIS

Randomized Prospective Trial of Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer
Cancer Services Breast Dr. Steven Papish

COMING SOON
ER+/HER2- locally advanced/metastatic Breast Cancer

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy
Cancer Services Gastrointestinal  Dr. David Gallinson Colorectal Cancer - Registry NCT04264702 BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Cancer Services Gastrointestinal Dr. David Gallinson

Colorectal - Advanced Disease 2nd Line NCT04793958

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation
with Disease Progression On or After Standard First-Line Therapy
Cancer Services Gastrointestinal Dr. David Gallinson

Colorectal - metastatic braf v600e NCT04607421

An open-label, multicenter, randomized phase 3 study of First-line encorafenib plus cetuximab with or without Chemotherapy versus standard of care therapy with a safety Lead-in of encorafenib and cetuximab plus chemotherapy inParticipants with metastatic braf v600e-mutant colorectal Cancer
Cancer Services Gastrointestinal Dr. David Gallinson

Metastatic Neuroendocrine Tumors

An Expanded Access Program Of Surufatinib For Patients With Advanced Or Metastatic Neuroendocrine Tumors
Cancer Services Gastrointestinal Dr. David Gallinson

Metastatic Cholangiocarcinoma NCT03656536

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter
Study to Evaluate the Efficacy and Safety of Pemigatinib Versus
Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With
FGFR2 Rearrangement (FIGHT-302)
Cancer Services Gastrointestinal Dr. David Gallinson

Pancreatic Cancer - 2nd Line NCT04825288

A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer
Cancer Services Gastrointestinal Dr. David Gallinson

COMING SOON
Metastatic colorectal cancer NCT04444622

Phase II open-label study to assess the safety and efficacy of stimvax® as third line therapy for metastatic colorectal cancer.
Cancer Services Gastrointestinal Dr. David Gallinson

COMING SOON
Metastatic Colorectal cancer NCT05141721

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer
Cancer Services Genitourinary Dr. Jeffrey Becker

high-grade NMIBC NCT05085977

A Phase 1 a/b dose finding open label study to evaluate safety and toxicity of intravesical instillatin of TARA-002 in adults with hight grade NMIBC
Cancer Services Genitourinary Dr. William Brown

NMIBC-Unresponsive/High-Risk NCT04752722

A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Or Docetaxel/Prednisone Plus Afuresertib in Patients with Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Cancer Services Genitourinary Dr. Louis Keeler

Arquer Dx CUSP - ADX Bladder

Collecting plasma samples from CRPC patients to support the analytical validation of a novel liquid-based companion in vitro diagnostic test.
Cancer Services Genitourinary Dr. Joshua Wein

CG Oncology BOND 003 NCT04452591

Phase 3 Study of CG0070 in Patients with Non-muscular Invasive Bladder Cancer Unresponsive to BCG
Cancer Services Genitourinary Dr. William Terens

Vaxiion NCT 03854721

Phase 1 Safety and Tolerability of Intravesical VAX014 for Instillation in Subjects with Non Muscular Invasive Bladder Cancer
Cancer Services Genitourinary Dr. Christopher Wright

Bladder Cancer

A pivotal longitudinal study of the URO17 bladder cancer recurrence test as an indicator of tumor recurrence in patients
Cancer Services Genitourinary Dr. William Brown

ON HOLD
MIBC NCT04658862

Phas 3 multi center, randomized study evaluating efficacy of TAR-200 in combination with cetrelimab vs concurrent chemorradiotherapy in participants with MIBC of the bladder who are not receiving radical cystectomy
Cancer Services Genitourinary Dr. William Brown
Dr. Elan Diamond

Invasive Urothelial Carcinoma w/FGFR3 alteration NCT04197986

Phase 3 Multi Center Double Blind Randomized Placebo Controlled trial of infigratinib for the adjuvant treatment of subjects with invasive UC with susceptible FGFR3 genetic alterations
Cancer Services Genitourinary Dr. William Brown

Prostate Cancer

Evaluation of Prompt PGS Clinical Validity in African American
Cancer Services Genitourinary Dr. Mutahar Ahmed

Prostate Cancer NCT04263025

Prospective, Controlled Study Evaluating Recovery of Potency and Continence Following Robot-Assisted Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
Cancer Services Genitourinary Dr. Eric Margolis
Dr. Elan Diamond 

nmCRPC NCT04122976

Darolutamide observational study in nmCRPC patients
Cancer Services Genitourinary Dr. Elan Diamond

mCRPC NCT04060394

A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Or Docetaxel/Prednisone Plus Afuresertib in Patients with Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Cancer Services Genitourinary Dr. William Brown

CRPC NCT04157088

A randomized open label phase 2b study to evaluate physical function, including balance and daily activity in participants with CRPC treated with darlutamide or enzalutamide
Cancer Services Genitourinary Dr. Elan Diamond

mCRCP NCT03574571

DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223
for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Cancer Services Genitourinary Dr. Elan Diamond

Muscle-invasive Bladder Cancer NCT05221827

Clinical Performance Evaluation of the C2i-WGS-MRD Test for detecting molecular residual disease (MRD) in bladder cancer patients
Cancer Services Genitourinary Dr. Benjamin Freeman

Metastatic Castration-resistant Prostate Cancer NCT04100018

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)
Cancer Services Genitourinary Dr. Stuart Shoengold

Female Sexual Arousal Disorder (FSAD) NCT04948151

A phase 2b, multi-center, multiple-dose, double-blind, placebo-controlled study to evaluate the efficacy and safety of sildenafil cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD)
Cancer Services Genitourinary  

OAB/BPH Urovant URO-901-3005 Courage NCT04103450

A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Cancer Services Genitourinary  

BPH - (Device) Urotronic PR1087 Pinnacle NCT04131907

A prospective, multicenter, double blind, randomized, clinical study to evaluate the safety and efficacy of the Optilume™ BPH Catheter System in men with symptomatic BPH
Cancer Services Genitourinary  

ON HOLD
Urinary Retention Spinal Singularity  C2P-01 NCT03626324

Evaluation of the Safety and Clinical Performance of the Gen 2 Connected Catheter –Wireless Urinary Prosthesis for Management of chronic Urinary Retention
Cancer Services Genitourinary  

Bladder Denervation (Device) Hologic 1360-001 (Transform) NCT04408352

Selective Bladder Denervation Using RF Energy for The Treatment of UUI
Cancer Services Genitourinary  

Recurrent UTI GSK 204989 NCT04020341

Phase 3, randomized, multicenter, parallel-group, double-blind, double-dummy study in females comparing the efficacy and safety of gepotidacin to nitrofurantoin in the treatment of uncomplicated UTI *Study Visits @ Mt. Laurel only
Cancer Services Genitourinary  

Renal Calculi  (Device) Calyxo ASPIRE 212390

A Prospective, Randomized Study to Evaluate the Safety and Effectiveness of Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC™ Aspiration System Compared to
Basketing for the Removal of Renal Calculi Following Ureteroscopic Laser Lithotripsy
Cancer Services Genitourinary  

Hypogonadal Men Acerus NAT2020-01 NCT04976595

24 hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Treated with Natesto Nasal Testosterone Gel
Cancer Services Hematology Dr. Benjamin Freeman

CLL-Previously treated  (Acalabrutinib) NCT04116437

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment Acalabrutinib
Cancer Services Hematology Dr. Benjamin Freeman

ENROLLMENT ON HOLD
CLL - TN or R/R NCT03801525

ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of
Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL)
Cancer Services Hematology Dr. David Gallinson 

CLL - Registry

Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment with Bruton’s Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib
Cancer Services Hematology Dr. Benjamin Freeman

DLBCL - Untreated High-Intermediate; High Risk 

This phase 3, multicenter, randomized, double-blind, placebo-controlled study is designed to investigate whether tafasitamab plus lenalidomide as add-on therapy to R-CHOP provides improved clinical benefit compared to R-CHOP in patients with newly-diagnosed high-intermediate and high-risk DLBCL.
Cancer Services Hematology Dr. Benjamin Freeman

DLBCL  - R/R  (2 or more prior lines) NCT04404283

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Cancer Services Hematology Dr. KarLeung Siu

ON ENROLLMENT HOLD                             Follicular Lymphoma R/R NCT04699461

A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma
Cancer Services Hematology Dr. David Gallinson

Mantel Cell (Registry) NCT03816683

Treatment Patterns, Outcomes, and Patient-Reported Health-Related
Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell
Lymphoma Treated with Novel Agents
Cancer Services Hematology Dr. David Gallinson

Cohort 1 enrollment closed - only R/R MZL
R/R Grades 1-3a FL, MZL, MCL,1st line/ R/R CLL/SLL NCT04014205

A Phase I,Multicenter, Open-Label, Dose Escalation Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, ICP-022, in Patients with Relapsed/Refractory B-Cell Malignancies
Cancer Services Hematology Dr. KarLeung Siu

Myelofibrosis - Treatment Naïve NCT04603495

A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (MANIFEST-2)
Cancer Services Hematology Dr. KarLeung Siu

Myelofibrosis NCT04468984

Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed /Refractory Myelofibrosis (TRANSFORM-2)
Cancer Services Hematology Dr. David Gallinson

COMING SOON
CLL/SLL/NHL 2021-760-GLOB1

A Multicenter, Open-Label Phase 1 Study Evaluating the Safety and Tolerability of
HMPL-760 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL)
Cancer Services Hematology Dr. David Gallinson

COMING SOON
R/R Lymphoma NCT03779113

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
Cancer Services Thoracic/Head & Neck Dr. Sarada Gurubhagavatula 

Lung - Stage III NSCLC

Induction durvalumab followed by chemoradiation and consolidation durvalumab (MEDI4736) for stage III non-small cell lung cancer
Cancer Services Thoracic/Head & Neck Dr. KarLeung Siu

Lung - Extensive Stage Small Cell with Untreated Brain Mets

Chemotherapy and Atezolizumab for Patients with Extensive Stage Small Cell Lung Cancer (SCLC) with Untreated, Asymptomatic Brain Metastases
Cancer Services Thoracic/Head & Neck Dr. Sarada Gurubhagavatula

Lung - Stage III NSCLC

A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA)
Cancer Services Thoracic/Head & Neck Dr. Sarada Gurubhagavatula

Lung - Metastatic EGRF-mutant

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Cancer Services Thoracic/Head & Neck Dr. Sarada Gurubhagavatula

CLOSED TO ENROLLMENT
Previously Treated Advanced NSCLC NCT03906071

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Cancer Services Thoracic/Head & Neck Dr. Sarada Gurubhagavatula

COMING SOON
NSCLC - Stage 1A2-1A3 EGRFm NCT05120349

A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2)
Cancer Services Thoracic/Head & Neck Dr. Sarada Gurubhagavatula COMING SOON
NSCLC - Stage III NCT05211895
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8)
Cancer Services Basket Trials Dr. Steven Papish

Sold Tumors- NSCLC/CRC/Melanoma Registry

BESPOKE Study of ctDNA Guided Immunotherapy (BESPOKE IO)
Cancer Services Pending Dr. David Gallinson

PENDING
Gastric - FGFR2b Overexpression NCT05111626

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus
Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Cancer Services Pending Dr. William DeRosa

PENDING
R/R MM CC-220-MM-002

A Phase 3, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) verses Daratumumab, Bortezomib, and examethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma
Cancer Services Pending Dr. William DeRosa

PENDING
DLBCL/FL/PMBCL registry CONNECT NHL Registry NCT04982471

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Cancer Services Pending Dr. Benjamin Freeman

PENDING
B-Cell Malignancies ML43389

An open-label, multicenter, phase ii trial Evaluating the safety, efficacy, and Pharmacokinetics of subcutaneous Mosunetuzumab monotherapy in patients With select b-cell malignancies
Cancer Services Pending Dr. Steven Papish

PENDING
Solid Tumors 2020-013-00US3

An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
Cancer Services Pending Dr. KarLeung Siu PENDING
Oropharyngeal Cancer MNPR-301-001 (VOICE)
A Phase 2b/3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety
of clonidine mucoadhesive buccal tablet to placebo to prevent chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer